ArticleScience translational medicine2011
IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.
Article in Science translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 113 citations in OpenAlex.
- Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.British journal of clinical pharmacology · 2019Trial
- Cellular immune responses in multiple sclerosis patients treated with interferon-beta.Clinical and experimental immunology · 2013Trial
- Nonlinear associations of plasma IL-9 with depression and anxiety symptoms in first-episode, drug-naïve major depressive disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- Selective inhibition of mitochondrial Kv1.3 prevents and alleviates multiple sclerosis in vivo.EMBO molecular medicine · 2025Article
- TRAF3 is critical for initial T follicular helper cell specification via coordination of the IL-6R/IL-2R-BCL6 signaling nexus.Science immunology · 2025Article
- IL-7 in autoimmune diseases: mechanisms and therapeutic potential.Frontiers in immunology · 2025Review
- Integrated analysis of rectal mucosal microbiome and transcriptome reveals a distinct microenvironment among young MSM.JCI insight · 2024Article
- IL-7Rα on CD4Journal of neuroinflammation · 2024Article
- Obesity intensifies sex-specific interferon signaling to selectively worsen central nervous system autoimmunity in females.Cell metabolism · 2024Article
- Association between type 1 diabetes and systemic lupus erythematosus: a Mendelian randomization study.Clinical rheumatology · 2024Article
- A genome-wide association study of blood cell morphology identifies cellular proteins implicated in disease aetiology.Nature communications · 2023Article
- IL-7 Deficiency Exacerbates Atopic Dermatitis in NC/Nga Mice.International journal of molecular sciences · 2023Article
- Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets.Pharmaceutics · 2023Review
- Apicobasal transferrin receptor localization and trafficking in brain capillary endothelial cells.Fluids and barriers of the CNS · 2023Article
- T-cell surveillance of the human brain in health and multiple sclerosis.Seminars in immunopathology · 2022Review
- Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.Journal of neuroinflammation · 2022Observational
- Heritability Estimation of Multiple Sclerosis Related Plasma Protein Levels in Sardinian Families with Immunochip Genotyping Data.Life (Basel, Switzerland) · 2022Article
- Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- IL-7 Promotes the Expansion of Circulating CD28- Cytotoxic T Lymphocytes in Patients With IgG4-Related DiseaseFrontiers in immunology · 2022Article
- Transcription Factor RUNX3 Mediates Plasticity of ThGM Cells Toward Th1 Phenotype.Frontiers in immunology · 2022Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
The interleukin-7 receptor α chain (IL-7Rα) gene was identified as a top non-major histocompatibility complex-linked risk locus for multiple sclerosis (MS). Recently, we showed that a T helper 1 (T(H)1)-driven, but not a T(H)17-driven, form of MS exhibited a good clinical response to interferon-β (IFN-β) therapy. We now demonstrate that high serum levels of IL-7, particularly when paired with low levels of IL-17F, predict responsiveness to IFN-β and hence a T(H)1-driven subtype of MS. We also show that although IL-7 signaling is neither necessary nor sufficient for the induction or expansion of T(H)17 cells, IL-7 can greatly enhance both human and mouse T(H)1 cell differentiation. IL-7 alone is sufficient to induce human T(H)1 differentiation in the absence of IL-12 or other cytokines. Furthermore, targeting IL-7/IL-7Rα is beneficial in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Mice treated with IL-7Rα-blocking antibodies before or after onset of paralysis exhibited reduced clinical signs of EAE, with reduction in peripheral naïve and activated T cells, whereas central memory T, regulatory T, B, and natural killer cell populations were largely spared. IL-7Rα antibody treatment markedly reduced lymphocyte infiltration into the central nervous system in mice with EAE. Thus, a serum profile of high IL-7 may signify a T(H)1-driven form of MS and may predict outcome in MS patients undergoing IFN-β therapy. Blockade of IL-7 and the IL-7Rα pathway may have therapeutic potential in MS and other autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.